We demonstrated that Val-ILs-αCD11b efficiently targeted CD11b+ cells, including MDSC, within the spleen 18 h after i.v. injection, but not in EL4 lymphoma (Fig. 6A). This evidence concerns the gene ITGAM and lymphoma.